<img src="https://ml.globenewswire.com/Resource/Download/bc26a912-b583-43c6-8423-55a4ba2bf4bd?size=2" nborder="0" align="left" hspace="5" vspace="5" title="spyre-logo-horizontal-full-color-rgb-583px@300ppi.jpg" alt="Spyre Therapeutics, Inc."/>WALTHAM, Mass., Sept. 04, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 2,106 shares of common stock of Spyre and 745 restricted stock units (“RSUs”) to one non-executive employee as an equity inducement award under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options and RSUs were approved on September 1, 2026 and were material to the employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options were granted with a 10-year term and an exercise price equal to $88.50, the closing price per share of Spyre's common stock as reported by Nasdaq on September 1, 2026. The options granted to the employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The RSUs granted to the employee shall vest as to one-fourth (1/4th) of the shares subject to the respective RSUs on each anniversary of the next February 15, May 15, August 15, or November 15 occurring on or after the employee’s start date, subject to continuous service with Spyre through the applicable vesting dates. The stock options and RSUs are subject to the terms of the 2018 Plan. About Spyre Therapeutics Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as well as rational combination programs. For more information, please visit http://spyre.com. For Investors: Eric McIntyre SVP of Finance and Investor Relations Spyre Therapeutics Eric.mcintyre@spyre.com <img alt="" src='https://ml.globenewswire.com/media/YmQ1OGQwMTAtMmM0YS00MTdmLThjNGUtOWExOGFmMzJhMmJjLTEzMDYzNjMtMjAyNi0wOS0wNC1lbg==/tiny/Spyre-Therapeutics-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

Spyre Therapeutics Announces Grants of Inducement Awards

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn